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Summary 
Normal human bone marrow cells, highly enriched for burst-forming units-erythroid (BFU-E), 
were cultured in serum-free medium, in the presence and absence of various factors, to investigate 
the mechanisms involved in regulating erythroid differentiation. In cultures containing interleukin 
3 (IL-3), Steel factor (SF), and erythropoietin (Ep), benzidene-positive erythroblasts first became 
detectable on day 6. Their numbers then rapidly increased until, by day 16, >99%  of the cells, 
which were 20,000-fold amplified over input numbers, were benzidene-positive. It is interesting 
to note that omission of either SF or Ep from this assay markedly enhanced the rate of differentiation 
and reduced total cell numbers, whereas omission of IL-3 had no effect on the rate of differentiation 
and only slightly reduced cell numbers. Of various agents tested, the most potent  erythroid 
differentiation inducer (and inhibitor of cell proliferation) was found to be transforming growth 
factor ~81 (TGF-~I). This cytokine stimulated both the rapid appearance of hemoglobin-positive 
cells and an early cessation of cell proliferation.  Using fluorescently tagged antibodies to glycophorin 
A and fluorescence-activated cell sorter (FACS) analysis, this phenomenon was shown to be due 
to an early induction of erythroid differentiation rather than an aberrant production of hemoglobin. 
Methylcellulose assays indicated that the well-documented reduction of BFU-E colony numbers 
observed with TGF-~31 may actually be due to a TGF-Bl-induced "conversion" of BFU-E into 
colony-forming units-erythroid (CFU-E). Thus, in vivo, TGF-fll might serve, in part, to decrease 
the number of mature erythrocytes by stimulating BFU-E to skip  a number of cell divisions 
and differentiate early. 
T 
he intracellular mechanisms that regulate the prolifera- 
tion and differentiation of primitive erythroid progen- 
itor cells are still largely unknown.  This has been due, in 
large part, to the difhculties inherent in obtaining sufhciently 
large, homogeneous starting populations of primitive erythroid 
progenitors for biochemical analysis  and the difhculties in 
growing these cells under well-defined serum-free conditions. 
However, with recent improvements in cell sorting techniques 
(1) and with the optimization of growth conditions using 
readily available recombinant growth factors (1, 2), such studies 
have now become feasible.  In  this report  we present  our 
findings using an erythroid differentiation assay in which 
CD34+CD71hiCD45RA 1~ human bone marrow cells, puri- 
fied by FACS  |  were allowed to proliferate and differentiate 
into hemoglobin containing cells under serum-free conditions 
in  suspension cultures containing IL-3,  Steel  factor (SF) 1, 
1 Abbreviations used in this paper: BFU-E, burst-forming  units-erythroid; 
CFU-GEMM, CFU-granulocyte/erythroid/megakaryocyte/monocyte;  Ep, 
erythropoietin;  GH,  growth  hormone; HMBA, hexamethylene 
bisacetamide; LIE  leukemia inhibitory factor; MIP-lcx, macrophage 
inflammatory  protein 1 cr  SF, Steel factor. 
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erythropoietin (Ep), insulin, BSA, and iron-saturated trans- 
ferrin. Under the conditions used, cell numbers increased dra- 
matically, plateauing at 20,000-fold amplification by day 16 
of incubation. Moreover, by day 12, >99% of the cells were 
benzidine-positive. This assay system has allowed us to in- 
vestigate the consequences of various growth factor additions 
and withdrawals on the proliferation and differentiation of 
burst-forming units-erythroid (BFU-E). Our results suggest 
that SF and Ep may function in vivo to delay the erythroid 
differentiation of mature BFU-E and thus allow more cell 
divisions and increased numbers of mature red blood cells. 
TGF-B1,  on the other hand, may perform the opposite func- 
tion by prematurely triggering terminal erythroid differenti- 
ation in primitive erythroid progenitors and thereby reducing 
the overall  number of mature erythrocytes. 
Materials and Methods 
Reagents.  TGF-/31,  TNF-oe, and macrophage inflammatory pro- 
tein I oe (MIP-lc  0 were purchased from R & D Systems Inc. (Min- 
neapolis, MN). Recombinant human activin was a generous gift 
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SF was provided by Amgen Biologicals (Thousand Oaks, CA). 
Recombinant human IL-9 and IL-11 were from Genetics Institute 
(Cambridge, MA). PIXY was generously provided by Dr. D. E. 
Williams of Immunex (Seattle, WA). BSA (Fraction V, A4503), 
prostaglandin E~ and E~, human glucagon, human somatotropin 
(growth hormone [GH]), retinoic acid, spermidine,  thymidine,  hex- 
amethylene bisacetamide (HMBA), and low density lipoproteins 
(L2139) were all purchased from Sigma Chemical Co. (St. Louis, 
MO). DMSO was obtained from Fisher Scientific  (Vancouver, B.C., 
Canada). Recombinant human Ep and IL-3  were purified from cul- 
ture supernatants of baby hamster kidney cells expressing an Ep 
eDNA and COS cells transfected with human IL-3 eDNA, respec- 
tively, as described  previously (3). Leukemia  inhibitory factor (LIF) 
were generously provided as a COS cell supernatant from Dr. D. 
Metcalf (Walter and Eliza Hall Institute,  Melbourne, Australia). 
Human transferrin (iron-saturated) was purchased from ICN Im- 
munoBiological (Cat. no. 82-343; Costa Mesa, CA), and insulin 
from Collaborative Research Inc. (Cat. no. 40205; Waltham, MA). 
Monoclonal Antibodies.  Mouse  monoclonal  IgGl  antibodies 
specific for CD34 (8G12), CD71 (OKT9),  CD45RA (8d2), and 
glycophorin A (10F7MN) were purified from hybridoma tissue cul- 
ture supernatants using protein A or protein G ai~nity chroma- 
tography and labeled  with cyanin  5-succinimidylester  (Cy-5), FITC 
and R-phycoerythrin (PE) (for both 8d2 and 10FTMN), respec- 
tively, as described previously (1). 
Purification of Human BFU-E.  Heparinized bone marrow was 
obtained from informed and consenting  normal individuals  donating 
marrow for allogeneic transplantation or from vertebral bodies of 
cadaveric organ donors. Low-density cells (<1.077 g/cc) were iso- 
lated  using  Ficoll-Paque (Pharmacia LKB, Uppsala, Sweden), 
resuspended in Iscove's  medium with 50% FCS and DNase 1 (0.1 
mg/ml) (Cat. no. D4513; Sigma Chemical Co.), and then washed 
once and resuspended in Hank's Hepes-buffered  salt solution con- 
taining 2% FCS, 0.1% sodium azide (HFN), 0.1 mg/ml DNase 
1,  and 5%  normal human serum and incubated at 107 cells/ml 
simultaneously with 8G12-CyS, 8d2-PE, and OKT9-FITC at 10, 
4, and 1 #g/ml, respectively, for 30 rain at 4~  The cells were 
then washed twice in HFN and resuspended in HF containing 
propidium iodide (Cat. no. p-4170; Sigma Chemical  Co.) and sorted 
on a FACStar  §174  (Becton Dickinson & Co., Mountain View, CA) 
as described previously  (1). The sorted cells were either used directly 
or aliquoted  (20,000 cells/vial),  frozen  in Iscove's  medium containing 
2.5%  human serum albumin and 7.5%  DMSO, and stored at 
-  70oc. 
Serumfree  Suspension  Cultures.  On  day O,  fresh or  frozen 
CD34 +  CD71h~CD45RAl~  cells were washed with Iscove's MEM, 
resuspended in serum-free medium (2% BSA, 10/~g/ml insulin, 
200/~g/ml iron-saturated transferrin, 40 #g/ml low density lipo- 
proteins,  5  x  10-5M 2-mercaptoethanol, and penicillin/strep- 
tomycin at  102  U  and 50 /~g/ml, respectively) containing IL-3 
(20 ng/ml), SF (50 ng/ml), and Ep (1 U/ml) (1), unless otherwise 
indicated,  and  500-5,000 cells/well incubated  in  96-well flat- 
bottomed tissue culture plates (Nunc, Roskilde, Denmark) at 37~ 
in a water saturated atmosphere of 5%  CO2 for the next 16 d. 
The number of viable cells, using trypan blue, and the number 
ofbenzidene positive  cells (4) were determined over this 16-d  period. 
Assay for Clonogenic Cells.  Colony assays  for erythroid (CFU-E, 
BFU-E), granulocyte/macrophage (CFU-GM),  and multipotent 
CFU-granulocyte/erythroid/megakaryocyte/monocyte (CFU- 
GEMM) progenitors were performed in methylcellulose cultures 
as previously described (5), using MethoCult H4431 (Stem Cell 
Technologies, Vancouver,  BC, Canada) supplemented  with 20 ng/ml 
PIXY, and 50 ng/ml SF, unless otherwise indicated. 
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Results 
As a first step towards elucidating the regulatory mecha- 
nisms that control normal human erythropoiesis, a simple 
serum-free suspension assay was devised to monitor both the 
proliferation and differentiation of BFU-E from normal human 
bone marrow. For this, low density cells, obtained by Ficoll- 
Paque  centrifugation, were fractionated by FACS  |  using 
monoclonal antibodies  to  CD34,  the  transferrin receptor 
(CD71), and CD45RA, as described in Materials and Methods, 
and the selected cells, shown in Fig. 1 were then used directly 
or aliquoted at 20,000 cells/vial, frozen and stored at -70~ 
Typically, for the assay, 500-5,000  cells, in a final volume 
of 0.2 ml, were added per well to 96-well flat-bottomed tissue 
culture plates  containing IL-3, SF, and Ep in a serum-free 
medium previously selected for its ability to maximally stimu- 
late the proliferation of CD34 + cells in suspension cultures 
(1). As can be seen in Fig. 2 A, these culture conditions al- 
lowed for the rapid proliferation of these cells during the next 
16 d at 37~  at which time they plateaued at an ~20,000- 
fold amplification of starting cell numbers. Monitoring the 
number of benzidine-positive cells from these same cultures 
during this time period revealed that cells containing hemo- 
globin first appeared  on day 6 and their numbers increased 
steadily until, by day 12, >99% of the cells were benzidine- 
positive  (Fig.  2  B).  This  rate  of hemoglobinization was 
unaffected by the number of cells used to initiate the cul- 
tures, at least in the 500-5,000 cell range tested (data not 
shown). 
We then set out to determine the effect of omitting one 
or more of the three hemopoietic cytokines that were rou- 
tinely added to these cultures (Fig.  3).  It is interesting to 
note that leaving out SF decreased  total cell numbers and 
markedly enhanced the rate of erythroid differentiation of 
these cells. Also of interest was the finding that normal human 
BFU-E were capable of giving rise to hemoglobin-positive 
cells in the absence of Ep and actually did so at a substan- 
tially faster rate than in its presence. To ensure that these cells 
were not becoming hemoglobin-positive because  of a low 
level of endogenously produced Ep, these cultures were also 
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Figure 1.  Selection  of CD34 +, CD71  ~, CD45RAb cells from normal, 
organ donor bone marrow by flow cytometry.  CD34  + cells with a low 
side scatter (A) were sorted on the basis of CD45RA and CD71 fluores- 
cence as shown  in B. Dot blots were  derived  from  low-density,  propidium 
iodide-negative  cells.  Fluorescence  is plotted  on a log scale. The boxed  area 
indicates the criteria used for selection. 
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CD34 § ,  CD71 hi, CD45RA 1~ cells, purified from normal 
human bone marrow, were allowed to grow in serum-free suspension cul- 
tures as described in Materials and Methods and both total cell numbers 
(.4) and the percent benzidine positive cells (B) determined each day. Each 
point represents the mean  _+  SEM of duplicate samples. Similar results 
were obtained in 20 separate experiments. In this experiment, cultures 
were initiated with 500 cells/well. 
tested  in  the presence  of an excess  of neutralizing  anti-Ep 
26 monoclonal antibodies (6) (Fig. 3). As with SF, total cell 
numbers were reduced, but even more so than when SF was 
omitted,  consistent  with  the  antiapoptotic  role  recently 
reported for Ep (7-9).  Omitting IL-3 resulted in a slight de- 
crease in total cell numbers without  significantly  affecting 
the rate of erythroid differentiation. Adding three times the 
usual amount of IL-3, SF, and Ep to these cultures increased 
the total cell counts two to threefold but had no effect on 
their  rate of differentiation  (data  not  shown). 
We next examined the effect of various factors that, from 
the literature,  might be expected to have an influence in our 
assay system. These included TGF-/~I, MIP-loz, and glucagon; 
which have been shown previously to inhibit erythropoiesis 
under certain conditions (10-16);  activin, human somatotropin 
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Figure  3.  CD34 + , CD71 hl, CD45RA 1~ cells were allowed to grow in 
the serum-free suspension assay in the presence and absence of Ep, IL-3, 
and SF and the percent benzidine-positive (/1) and total cell numbers (B) 
determined on days 7, 8, and 9 of culture. Standard  conditions (D); without 
SF (O); without Ep plus anti-Ep 26 (6) (11); without Ib3 (O). Cultures 
were initiated with 700 cells/well and each point represents the mean _+ 
SEM of duplicate samples. 
(GH),  prostaglandins  Et and E2,  LIF,  human IL-9,  and IL- 
11, all of which have been reported to increase erythroid colony 
numbers  in  methylcellulose  (17-23);  and TNF-cq  activin, 
TGF-31,  retinoic acid, spermidine, HMBA, DMSO,  and the 
cell cycle blockers thymidine,  aphidicolin,  and 5-azacytidine, 
all  of which  have been  shown  to  induce  differentiation  in 
some systems (24-40).  We tested these reagents over a wide 
range of concentrations  and the results,  shown in Table  1, 
are those obtained with  concentrations  that  gave the most 
pronounced effects on differentiation.  Agents that increased 
the rate of differentiation, and concomitantly decreased total 
cell numbers in this suspension assay included activin A, the 
cell cycle blockers, thymidine and aphidicolin, and the MEL 
cell differentiation inducing agents, DMSO and HMBA. How- 
853  Krystal et al. Table  1.  Effect of Various Agents  on  the Proliferation and Differentiation  of CD34+CD71 ~' CD45RA 1~ Cells 
Experimental*  Control* 
MIP-lot  (500 ng/ml)  11%  (6.0  X  106)  13%  (6.0  X  106) 
TGF-~I  (20 ng/ml)  92%  (3.0  x  105)  18%  (1.0  x  106) 
Activin A  (120 ng/ml)  29%  (1.1  x  107)  17%  (1.1  x  107) 
AphidicolinS  (5 /zg/ml)  59%  (3.2  x  104)  13%  (1.2  ￿  10  6) 
5-azacytidine  s  (0.5 mM)  12%  (5.7  x  105)  15%  (5.4  x  105)11 
ThymidineS  (100 #M)  52%  (1.6  ￿  105)  22%  (3.5  x  106) 
Glucagon  (100/~g/ml)  18%  (1.0  X  10  6)  18%  (1.0  X  10  6) 
HMBA  (2.5 mM)  30%  (1.1  x  106)  13%  (6.0  ￿  10  6) 
DMSO  (1%)  30%  (1.1  x  106)  13%  (6.0  ￿  106) 
hGH  (100 ng/ml)  10%  (1.0  ￿  106)  13%  (6.0  x  106) 
PGE1  (100 nM)  35%  (1.2  x  105)  37%  (1.3  x  105)11 
PGE2  (100 nm)  43%  (7.8  x  104)  37%  (1.3  x  106) 
LIF  (100 ng/ml)  17%  (8.0  ￿  106)  13%  (6.0  x  106) 
hlL-9  (100 ng/ml)  9%  (7.0  x  10 6)  13%  (6.0  x  10 6) 
hlL-11  (100 ng/ml)  33%  (1.4  x  106)  37%  (1.3  x  106) 
Retinoic acid  (2 /zM)  20%  (1.1  x  106)  13%  (6.0  x  106) 
Spermidine  (3 nM)  19%  (0.7  x  106)  26%  (2.0  X  10 6) 
TNF-a  (50 ng/ml)  37%  (5.2  x  l0  s)  37%  (1.3  ￿  10 6) 
* Percent refers to percent of benzidine positive cells on day 7. Numbers in parentheses refer to total cell number on day 7. 
* Percent and numbers in parentheses refer to benzidine positive and total cell numbers, respectively,  of control cultures obtained on day 7 within 
the same experiment. 
Added to cultures on day 4. 
II These assays were initiated with 500 cells/well, the rest were started with 5,000 cells/well. 
ever, the most potent agent in this regard was the growth 
factor,  TGF-/31 (Table 1).  We therefore set out to examine 
the effect of this cytokine more closely in our assay system. 
A TGF-/31 dose-response  analysis was carried out and re- 
vealed that as little as 0.4 ng/ml significantly reduced the 
time required for 50% of the cells to become hemoglobin- 
positive (Fig. 4). At 4 ng/ml of TGF-/31, >50% of the cells 
were  hemoglobin-positive by day 4.  Similar  numbers  of 
hemoglobinizing cells were not observed in control cultures, 
containing SF, IL-3, and Ep, until day 9 (Fig.  4 A). At 40 
ng/ml of TGF-~I, >90% of the cells were hemoglobinized 
within 4 d and the cells were more darkly stained and smaller 
than the benzidine positive cells in the 4 ng/ml TGF-~I cul- 
ture. Also, as expected, an inverse correlation was observed 
between TGF-~I concentration and total cell output, with 
TGF-B1 causing a plateau in cell numbers earlier than in con- 
trol cultures (Fig. 4 B). These studies also revealed that TGF- 
/51 stimulated an increase in the absolute number (and not 
just the percent) of benzidine positive cells (Fig. 4 C), con- 
sistent with the notion that this cytokine is stimulating an 
increased  rate of erythroid differentiation and not simply a 
growth inhibition of more primitive erythroid progenitors 
in the cell population. 
A delayed addition study was then carried out with TGF- 
/31 to gain some insight into the target cell for the effects 
observed here. As can be seen in Fig. 5, TGF-/31 stimulated 
differentiation and started inhibiting total cell output within 
24 h of addition, regardless of when it was added. This sug- 
gests that most if not all erythroid progenitors, from BFU-E 
onward, are  target cells for TGF-/31. 
Many reports in the literature have suggested that TGF- 
/31 inhibits BFU-E formation (41-45).  From our suspension 
culture data, it appeared possible that TGF-B1 might be in- 
hibiting BFU-E proliferation without blocking differentia- 
tion, thus effectively "converting" BFU-E into CFU-E. To 
test this,  CD34+CD71hiCD45RAl~ cells were cultured in 
complete methylceUulose medium to allow the clonal progeny 
of each initial cell to be evaluated over time. As can be seen 
in Table 2, the overall plating efficiency of the cells in control 
cultures containing IL-3, SF, and Ep, was the same as cul- 
tures containing TGF-~81 (i.e., 50-60%).  In the presence of 
TGF-/31,  however,  there was a  substantial decrease  in the 
number of large erythroid colonies (normally scored as BFU-E 
derived)  and a concomitant increase in the number of small 
erythroid colonies (normally scored as CFU-E derived).  It 
is interesting to note that the total number of erythroid colony 
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numbers  was  not  affected  by  the  presence  of  TGF-~I, 
confirming  that TGF-~I  was not giving the appearance of 
speeding  up  hemoglobinization  by  simply  inhibiting  the 
growth of more immature  erythroid progenitors. 
To confirm that TGF-B1 was indeed inducing the erythroid 
differentiation  of CD34+CD71hiCD45RA 1~ cells  and  not 
just turning  on hemoglobin synthesis and also to more ac- 
curately quantitate the absolute numbers of cells differentiating 
in the presence and absence of TGF-B1, a second marker of 
erythroid differentiation,  glycophorin A, was examined by 
FACS  |  analysis. A time course revealed that, by day 2, TGF- 
B1  had  dramatically  increased  the  absolute  number  of 
glycophorin A + cells, even though total cell numbers were 
decreased (Fig.  6).  It is interesting  to note that  in control 
cultures, the majority of differentiating cells lost CD34 from 
their surfaces before expressing glycophorin. In contrast, when 
cells were incubated with TGF-~I, the bulk of glycophorin 
A + cells were also CD34 +, perhaps reflecting the fewer cell 
divisions these cells go through in the presence of this cytokine. 
Consistent with this notion, the total number of cells plateaued 
on day 7 in the presence of TGF-B1 while control cultures 
continued to increase their total cell numbers until day 12 
(data not  shown). 
Discussion 
In  this  report  we describe the  use of a  16-d  erythroid 
differentiation assay to examine the effects of various agents 
on  the  proliferation  and  differentiation  of normal  human 
BFU-E. Under the standard culture conditions of this assay, 
the cells differentiate in a synchronous fashion and cell prolifer- 
ation plateaus at an ~20,000-fold amplification which sug- 
gests, given a 50-60% plating ef~ciency,  that these cells di- 
vide  approximately  16  times  before  arresting  (assuming 
minimal cell death).  Omission of SF or Ep from these cul- 
tures enhances differentiation  and reduces the proliferation 
potential of the starting cell population to approximately 10 
divisions (again assuming minimal cell death, which is overly 
simplistic, given the antiapoptotic properties of these cytokines 
[7-9,  46]).  This could suggest that,  in vivo, both SF  and 
Ep function to delay the onset of differentiation, thus allowing 
more cell divisions and an increase in the numbers of mature 
red blood cells.  In the case of SF, this is consistent with  a 
very recent report by Ogawa et al.  (47), who showed that 
SF inhibits  the erythroid differentiation  of K562 cells.  Al- 
though postulating such a function for Ep may be somewhat 
heretical it is supported to some extent by very recent experi- 
ments using an MEL cell line transfected with a temperature- 
sensitive mutant of p53 (48). At the permissive temperature 
these cells arrest in the Go/G1 phase of the cell cycle, rapidly 
lose viability and express hemoglobin.  However, when Ep 
DAY 
Figure 4.  CD34  +  , CD71  hi, CD45RA  lo cells were suspended in the 
standard suspension culture assay in the absence (VI) and presence of 0.4 
ng/ml (I), 4 ng/ml (O), and 40 ng/ml (Q) TGF-B1 and percent benzidine- 
positive (A) and total cell numbers (B) determined daily. C is a replotting 
of the data for the control (El) and 40 ng/ml TGF-3I (Q) cultures to 
indicate the total number ofbenzidine  positive  cells. Each point represents 
the mean + SEM of duplicate samples. In this experiment, cultures were 
initiated with 5,000 cells/well. 
855  Krystal  et al. Table  2.  Effect of TCF-fll  on Colony Formation from  CD34+,CD71 ~ CD45RA 1~ Cells* 
Addition  CFU-E  Mature  BFU-E  Immature BFU-E  CFU-GEMM  CFU-GM  Total Colonies 
Control  10+  2  55_+  2  38_+4  6  +  2  3  +  1  112_+  10 
TGF-~I  (20  ng/ml)  92  +  4  12  _+ 2  0  1  +  1  1  _+  1  106  _+ 8 
* Methycellulose  assays were performed using 200 cells/dish  in MethoCult H4431  (i.e.,  30% FCS, 10% agar leukocyte conditioned  medium, 1% 
BSA,  10-4M 2-mercaptoethanol,  3 U/ml Ep, and 2 mM glutamine)  supplemented with 20 ng/ml PIXY and 50 ng/ml SF. Similar results were ob- 
tained in three separate experiments. 
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Figure  5.  A delayed addition study with TGF-~I.  Individual suspen- 
sion cultures, containing CD34 § , CD71 hl, CD45RA  lo cells and growing 
under standard conditions, were supplemented or not (D) with 4 ng/ml 
TGF-31  on day 1 (11),  day 3 (O), day 5 (e), day 7 (A), or day 9 (A) 
and both percent benzidine positive (.4) and total cell numbers (B) deter- 
mined daily. Cultures  were initiated with 700 cells/well. 
is added to these cultures it prolongs their survival and dimin- 
ishes the extent of hemoglobin  production.  It is  therefore 
conceivable that Ep delays the terminal erythroid differentia- 
tion program of primitive progenitors (i.e., mature BFU-E 
and CFU-E) while promoting this same program in more 
mature precursors  (i.e., proerythroblasts and normoblasts). 
Of the various  agents  added  to  this  assay, DMSO  and 
HMBA, two agents that have been shown previously to stimu- 
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Figaro  6.  A time course study showing the effect of TGF-B1 on the 
generation of glycophorin A + cells. TGF-B1 was added to 10 ng/ml. The 
numbers in the boxed off areas indicate cell numbers in these areas. 
856  TGF-31  Is an Inducer of Erythroid Differentiation late the differentiation of Friend virus-transformed murine 
erythroid cells (i.e., MEL cells) were found to significantly 
increase the rate of differentiation and concomitantly decrease 
the rate of proliferation of normal human erythroid progen- 
itors. This not only adds further credibility to the use of the 
MEL cell system for studying normal erythroid differentia- 
tion but indicates that DMSO and HMBA act across species 
barriers. Agents shown to have effects in other systems which 
were found to not significantly affect this assay included MIP- 
lc~, glucagon, growth hormone, the prostaglandins El, and 
E2, LIF, IL-9, IL-11, retinoic acid, spermidine, and TNF-a. 
Based on our data and results obtained from other studies 
it is likely these agents were without effect because their target 
cells are not BFU-E or that they do not act directly on BFU-E; 
i.e., they may stimulate the release of factors by accessory cells 
that affect BFU-E differentiation. 
It is interesting to note that of the various agents added 
to this assay, TGF-31 gave the most profound effects. This 
ubiquitous cytokine is produced by most normal tissues (49) 
and vitally transformed cells (50,  51) and has been reported 
to act as a chemotactic factor (52),  an enhancer of integrin 
expression and type IV collagenase secretion in monocytes 
(53), a mitogen (54), a growth inhibitor (55, 56), a differen- 
tiation inhibitor (57), and a differentiation inducer (58, 59). 
It is found at high concentrations in the centers of active tissue 
differentiation, including bone marrow and areas containing 
hemopoietic stem cells in fetal liver (60), consistent with its 
putative in vivo role as a differentiation inducer. In both human 
and murine primary bone marrow cell cultures, TGF-3 has 
been reported to inhibit both multilineage colony formation 
(CFU-GEMM) and BFU-E, while stimulating CFU-E (43, 
44, 61). Our delayed addition and methylcellulose assay results 
with TGF-B1 suggest that this is not due to an inhibition 
of BFU-E growth and a stimulation of CFU-E numbers but 
rather to a conversion of BFU-E into CFU-E. This is further 
supported by the earlier cessation of cell proliferation (i.e., 
plateauing of cell numbers) observed in the presence of TGF- 
/~1 (see Figs.  4 and 5). It is interesting to note that studies 
carried out with the multipotential human erythroleukemic 
cell line, K562, have shown that TGF-/31, and to a lesser ex- 
tent, activin, could induce hemoglobin accumulation and a 
concomitant reduction in proliferation and cell size  (23), 
reminiscent of the effects we report herein with normal human 
bone marrow-derived BFU-E. Other studies using K562 cells 
have revealed that it can also be induced to hemoglobinize 
with agents that halt cell division, like 5-azacytidine (62), 
adriamycin (63), arabinofuranosylcytosine (64), and aphidicolin 
(37).  The ability of TGF-fl to induce erythroid differentia- 
tion in this cell line thus may depend upon its ability to in- 
hibit cells from entering S phase, and there is a growing con- 
sensus  that  TGF-/3  mediates its  effects on target  cells by 
arresting or delaying cells in G1 of the cell cycle. This is con- 
sistent with our finding that two agents that normally in- 
hibit entry into S, i.e., thymidine and aphidicolin, also stimu- 
lated hemoglobinization in our assay. The mechanism by 
which TGF-fll inhibits erythropoietic proliferation is not com- 
pletely understood although there is some evidence to sug- 
gest that it may do so, at least in part, by maintaining the 
retinoblastoma (Rb) growth suppressor protein in an active, 
underphosphorylated state (65, 66). In fact, very recent results 
with human keratinocytes and mink lung epithelial cells sug- 
gest that it may do this by either inhibiting the synthesis 
of the cyclin dependent kinase (and/or its associated cyclin) 
that phosphorylates Rb (67,  68) or by blocking the forma- 
tion of this cyclin-kinase complex (69). An alternative to this 
model is  that TGF-fll  may inhibit  cell cycling by down- 
modulating the expression of growth factor receptors (70). 
For example, downmodulation of IL-1 receptors by TGF-fl 
has been proposed as a mechanism of TGF-fl-induced inhi- 
bition of IL-1 action (71). TGF-fl has also been reported to 
modulate the expression of GM-CSF, IL-3, and CSF-1 receptor 
numbers (71-73)  and has recently been shown to interfere 
with the proliferation-inducing activity of SF in myeloge- 
nous blasts,  possibly through functional downregulation of 
the c-kit protooncogene (71). Since we observed a profound 
erythroid differentiating effect when SF was omitted from 
our assay medium, and a drop in total cell numbers equal 
to that obtained with TGF-B1, it is conceivable that TGF-/31 
stimulates  BFU-E  differentiation by downmodulating SF 
receptors. We are currently investigating whether effects on 
suppressor protein phosphorylation and/or receptor modu- 
lation are involved in the action of TGF-B1 on the immediate 
progeny of normal human BFU-E. 
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